Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
- None.
- None.
Insights
An intriguing aspect of Artelo Biosciences' latest publication lies in the validation of FABP7 as a novel target in cancer therapies. The implications are significant, given that current treatments often have limitations in specificity and efficacy. By pinpointing a protein upregulated in multiple types of cancer, Artelo may be able to devise drugs with better outcomes, particularly in terms of patient prognosis.
When analyzing the preclinical success of ART26.12, the compound's potential benefits extend beyond cancer treatment alone to include alleviation of cancer bone pain and chemotherapy-induced peripheral neuropathy (CIPN), a condition lacking FDA-approved management options. The bid to file an IND for ART26.12 could mark a substantial step forward in pain management for cancer patients, addressing a substantial unmet medical need.
From a financial perspective, Artelo's progress in the drug development pipeline is of substantial interest to investors. The move to file an IND represents a transition from research into potential commercialization, which can offer investors insights into the company's trajectory. The market for neuropathic pain management, particularly in connection with cancer treatment, is notably underserved. Should ART26.12 advance through clinical trials, it provides a clear pathway towards market entry in a niche with limited competition and potentially high demand.
Understanding the market dynamics for FABP7 inhibitors gives context to Artelo's strategic positioning. Their broad FABP inhibitor library and the specific focus on CIPN tap into a growing demand for cancer supportive care treatments. The statistics mentioned – approximately
Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article, “The emerging role of fatty acid binding protein 7 (FABP7) in cancers,” in Drug Discovery Today, a peer-reviewed journal. The article analyzes the results of various studies and presents a comprehensive analysis of FABP7’s role in a variety of cancers and its correlation with patient prognosis, as well as its potential utility as a validated target in cancer treatment.
The publication reveals that FABP7, an intracellular protein involved in the uptake, transportation, metabolism, and storage of fatty acids, is upregulated in several cancers including breast, brain, and kidney cancers and is generally associated with a poor patient prognosis. Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies. Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
“Artelo is dedicated to furthering research on FABP inhibition including selective- and pan-FABP inhibition, with the aim of providing new therapeutic options for patients battling cancer and other serious conditions,” said Professor Saoirse Elizabeth O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences. “The insights highlighted in this review continue to underscore the potential impact of our FABP inhibitor platform in several therapeutic areas.”
Artelo is currently evaluating multiple compounds for their therapeutic potential from the Company’s extensive FABP inhibitor library. The most advanced of these is ART26.12, a novel, potent and selective inhibitor of FABP5. In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN). Artelo plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) during the second quarter of 2024 for the development of ART26.12 in CIPN. Approximately
For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com
About ART26.12
ART26.12, Artelo’s lead Fatty Acid Binding Protein (FABP) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, cancer bone pain, neuropathic and nociceptive pain, dermatological and anxiety disorders.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and on X (formerly Twitter): @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, market opportunity, competitive position, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What is the focus of the peer-reviewed article published by Artelo Biosciences?
Which journal published the article on FABP7?
What are some cancers in which FABP7 is upregulated according to the publication?
What is the potential utility of FABP7 in cancer treatment?
Which compound is the most advanced in Artelo's FABP inhibitor library?
What is the therapeutic potential of ART26.12?
When does Artelo plan to file an IND application with the FDA for ART26.12 development?
What percentage of cancer patients treated with certain chemotherapies develop neuropathic pain?
Is there an FDA-approved therapy for chemotherapy-induced peripheral neuropathy?
